Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 18/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 10/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.46 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15920701 | 0.82 | S1PR3 (0.58) | S1PR3S1PR1S1PR4S1PR2AR | |
| SCHEMBL30737737 | 0.80 | S1PR3 (0.51) | S1PR3S1PR1S1PR4S1PR2AR | |
| SCHEMBL2369495 | 0.80 | S1PR3 (0.51) | S1PR3S1PR1S1PR4S1PR2AR | |
| SCHEMBL3615933 | 0.79 | KMT2A (0.59) | S1PR3 | |
| SCHEMBL22099996 | 0.78 | S1PR3 (0.54) | S1PR3S1PR1S1PR4S1PR2AR | |
| SCHEMBL996704 | 0.76 | MRGPRX4 (0.56) | S1PR3 | |
| SCHEMBL16961084 | 0.76 | S1PR3 (0.47) | S1PR3S1PR1S1PR4S1PR2AR | |
| SCHEMBL536163 | 0.76 | S1PR3 (0.51) | S1PR3S1PR1ARTP53 | |
| SCHEMBL7829370 | 0.76 | CHRNA1 (0.48) | TP53 | |
| SCHEMBL2767509 | 0.75 | S1PR3 (0.50) | S1PR3S1PR1S1PR4S1PR2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327512-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | SCRIPPS RESEARCH INST (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327512-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | SCRIPPS RESEARCH INST (US) | 2017-11-16 | — | — | US | disclosed |
| US-20150376198-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-31 | — | — | US | disclosed |
| US-20150376198-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-31 | — | — | US | disclosed |
| EP-2956441-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | The Scripps Research Institute (US) | 2015-12-23 | — | — | EP | disclosed |
| WO-2014127350-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376198-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | AVPR2, AVPR1A, AVPR1B | S1PR3 182/4885S1PR1 216/4885S1PR4 225/4885 |
| US-20170327512-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | AVPR2, AVPR1A, AVPR1B | S1PR3 182/4885S1PR1 216/4885S1PR4 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.